跳至主要内容
临床试验/EUCTR2020-004802-70-FR
EUCTR2020-004802-70-FR进行中(未招募)1 期

Impact of post-ARDS COVID sedation on late neuroinflammation - PET-DEXDO COVID

Assistance Publique – Hôpitaux de Paris0 个研究点目标入组 62 人开始时间: 2021年3月29日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
62

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Adult patient (age = 18 years at the time of inclusion) under 75 years old
  • COVID-19 infection documented by nasopharyngeal pCR test.
  • High affinity homozygous TPSO genotyping for the radiotracer or heterozygous intermediate affinity for the radiotracer
  • Patient who was hospitalized in intensive care for an ARDS following the COVID infection requiring mechanical ventilation and deep sedation for at least 48 hours.
  • Patient alive 12 months (+/- 3 months) after discharge from intensive care
  • Signature of free and informed consent
  • Patient affiliated to a social security scheme, excluding AME (state medical aid)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 31
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 31

排除标准

  • Protected adult (under legal protection, under guardianship or curatorship)
  • Pregnancy or breast-feeding
  • Allergy to dexmedetomidine
  • Contraindication to a PET or MRI examination
  • Severe renal failure
  • (creatinine clearance <30 ml / min)
  • Serious neurological history on admission to intensive care:
  • o Severe head trauma
  • o Insane state with loss of autonomy

研究者

相似试验

Impact of post-Acute respiratory distress syndrome ... | 临床试验